Equities

PRF Technologies Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PRFX:NAQ

PRF Technologies Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.95
  • Today's Change-0.03 / -1.01%
  • Shares traded234.48k
  • 1 Year change-80.91%
  • Beta0.5409
Data delayed at least 15 minutes, as of Feb 10 2026 17:22 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.

  • Revenue in USD (TTM)0.00
  • Net income in USD-4.09m
  • Incorporated2007
  • Employees2.00
  • Location
    PRF Technologies Ltd65 Yigal Alon St.TEL AVIV-YAFO 6744316IsraelISR
  • Phone+972 37177051
  • Fax+972 99542266
  • Websitehttps://prf-tech.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PRFX:NAQ since
announced
Transaction
value
DeepSolar-Business ActivityDeal completed18 Feb 202518 Feb 2025Deal completed-79.08%--
Data delayed at least 15 minutes, as of Feb 10 2026 17:22 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
American Green Inc-100.00bn-100.00bn1.30m6.00------------------------------------------------------------
Procyon Corp4.98m-312.97k1.53m19.00--0.7027--0.307-0.0387-0.03870.61380.28171.472.329.90262,338.40-10.081.19-12.701.4478.0774.40-6.840.86912.41--0.00--6.353.53-367.38--17.32--
Stemcell Holdings Inc9.98m3.10m1.64m------0.50080.16450.000080.000080.00030.00021.12--5.20--34.90--68.19--77.19--31.04------0.00--85.10--71.82------
Panacea Life Sciences Holdings Inc2.76m-7.67m1.69m40.00------0.6102-0.4554-0.45540.164-0.52550.15371.6210.1369,098.25-42.65-69.04---225.03-139.49-181.62-277.51-505.410.0285-2.122.58--46.59--12.33------
Onconetix Inc1.22m-50.85m1.85m5.00--0.5504--1.51-350.74-350.742.142.160.031.3124.33244,750.00-120.44-82.49-240.72-114.7185.41---4,015.56-4,434.980.0706-17.940.0453--4,216.95---57.44--44.62--
Bio Essence Corp565.67k-160.45k2.08m2.00------3.67-0.0042-0.00420.0149-0.08161.26--16.06282,835.00-35.64-40.94----69.2838.36-28.36-134.00---57.42-------17.08-286.98------
Universe Pharmaceuticals Inc17.86m-3.67m2.24m216.00--0.0399--0.1254-10.13-10.1339.1899.640.26025.881.3882,679.35-5.35-5.40-7.08-7.0935.2843.33-20.56-9.653.90-17.460.1416---22.44-10.2757.92--46.30--
PRF Technologies Ltd0.00-4.09m2.33m2.000.00990.1421----301.27301.270.0020.970.00----0.00-57.27-71.03-118.06-84.02------------0.00-------56.12------
SOHM Inc-100.00bn-100.00bn2.44m--------------------------------------------------------------
InVitro International716.89k6.22k2.56m16.00328.573.58--3.570.00040.00040.04020.03211.15------0.9957.891.098.83----0.86765.90---------5.111.33-87.77-16.14----
Scisparc Ltd-100.00bn-100.00bn2.97m2.00---------------1.46-----------63.15---90.87-------456.810.5151--1.04---54.64---22.69------
Jaguar Health Inc11.79m-40.29m3.00m49.00--0.7755--0.2545-54.06-54.0612.981.530.21840.20998.78240,510.20-76.04-90.27-152.77-144.3681.9275.33-348.22-458.250.5197-4.620.8759--19.7515.146.80------
Functional Brands Inc6.80m-377.56k3.31m32.00--2.38--0.4875-0.0546-0.05460.96140.08540.88730.352737.24212,408.80-4.93---9.96--91.06---5.55--0.4419-0.87230.6346---3.72--54.93------
Data as of Feb 10 2026. Currency figures normalised to PRF Technologies Ltd's reporting currency: US Dollar USD

Institutional shareholders

1.03%Per cent of shares held by top holders
HolderShares% Held
Two Sigma Securities LLCas of 30 Sep 202516.19k0.80%
UBS Securities LLCas of 31 Dec 20254.34k0.22%
Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2025193.000.01%
SBI Securities Co., Ltd.as of 31 Dec 20256.000.00%
Vanguard Personalized Indexing Management LLCas of 30 Sep 20250.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.